Pacer Advisors Inc. boosted its holdings in Cencora, Inc. (NYSE:COR – Free Report) by 2,682.3% in the fourth quarter, Holdings Channel reports. The institutional investor owned 561,655 shares of the company’s stock after acquiring an additional 541,468 shares during the quarter. Pacer Advisors Inc.’s holdings in Cencora were worth $189,699,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also added to or reduced their stakes in the stock. Sonoma Allocations LLC grew its stake in Cencora by 81.2% during the fourth quarter. Sonoma Allocations LLC now owns 1,337 shares of the company’s stock valued at $483,000 after acquiring an additional 599 shares in the last quarter. MV Capital Management Inc. bought a new position in Cencora in the fourth quarter valued at $122,000. Kovitz Investment Group Partners LLC increased its position in shares of Cencora by 728.5% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 34,067 shares of the company’s stock valued at $11,506,000 after purchasing an additional 29,955 shares during the last quarter. Vancity Investment Management Ltd purchased a new position in shares of Cencora during the fourth quarter worth approximately $248,000. Finally, T. Rowe Price Investment Management Inc. lifted its stake in Cencora by 160.1% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock worth $2,262,956,000 after purchasing an additional 4,123,795 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.
Cencora Price Performance
NYSE COR opened at $271.99 on Friday. Cencora, Inc. has a 1-year low of $244.82 and a 1-year high of $377.54. The business’s fifty day moving average price is $285.65 and its 200-day moving average price is $324.72. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59. The stock has a market capitalization of $52.92 billion, a price-to-earnings ratio of 20.86, a PEG ratio of 1.50 and a beta of 0.59.
Cencora declared that its Board of Directors has authorized a stock repurchase program on Thursday, May 21st that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to buy up to 3.9% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board believes its stock is undervalued.
Cencora Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Monday, June 1st. Investors of record on Friday, May 15th were given a dividend of $0.60 per share. The ex-dividend date was Friday, May 15th. This represents a $2.40 annualized dividend and a yield of 0.9%. Cencora’s payout ratio is 18.40%.
Analysts Set New Price Targets
Several analysts have weighed in on COR shares. Robert W. Baird lowered their price objective on Cencora from $420.00 to $339.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Weiss Ratings lowered shares of Cencora from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 22nd. Leerink Partners restated an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Morgan Stanley set a $342.00 target price on shares of Cencora in a research note on Friday, May 8th. Finally, Evercore set a $360.00 price target on Cencora in a research report on Wednesday, April 8th. Twelve equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $374.00.
Check Out Our Latest Research Report on COR
About Cencora
Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.
Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.
Featured Articles
- Five stocks we like better than Cencora
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.
